NewsBenzingaProgyny eleva la previsión de BPA ajustado para el ejercicio 2026 de $2.04-$2.10 a $2.09-$2.13 frente a $1.28 estimado; eleva la previsión de ventas para el ejercicio 2026 de $1.360B-$1.385B a $1.365B-$1.385B frente a $1.373B estimado Progyny eleva la previsión de BPA ajustado para el ejercicio 2026 de $2.04-$2.10 a $2.09-$2.13 frente a $1.28 estimado; eleva la previsión de ventas para el ejercicio 2026 de $1.360B-$1.385B a $1.365B-$1.385B frente a $1.373B estimado Benzinga 2026.11.04 21:18 (GMT+0) Open on Benzinga Other news David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes Bernstein Maintains Market Perform on Tyson Foods, Raises Price Target to $72 Broadcom Stock Is Up Tuesday: AI Chip Diversification, Dec. 9 Earnings, Analyst Targets Bernstein Downgrades PepsiCo to Underperform, Lowers Price Target to $128 If You Invested $1000 In Humana Stock 20 Years Ago, You Would Have This Much Today What's Going On With Ouster Stock Tuesday?